Pabst Patent Group LLP
Ameliorating systemic sclerosis with death receptor agonists
The present disclosure relates to methods and compositions for treating and/or preventing autoimmune fibrosis, such as systemic sclerosis (SSc; scleroderma). The method includes administering to a subject in need thereof an effective amount of a death receptor agonist. Suitable death receptor agonists include tumor necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL), agonistic death receptor antibodies, and variants, analogues, or derivatives thereof. The administration of the death receptor agonist blocks fibroblast or profibrogenic cell activation, and/or reduces or depletes myofibroblasts, thereby reducing or preventing systemic sclerosis.
THE JOHNS HOPKINS UNIVERSITY
A C A A A A C C A
A61K C07K A61K A61K A61P A61K C07K C07K A61K
inventional additional additional inventional additional inventional inventional additional inventional
Maureen Magdalena Seulki Martin G. Jong-Sung Yumin
Horton Scully Lee Pomper Park Oh